SCHEDULE: Nextech VI Oncology Discloses 6% Stake in Tyra Biosciences

Nextech VI Oncology SCSp and related entities have reported beneficial ownership of 6.0% of Tyra Biosciences, Inc. common stock as of June 30, 2026.

Summary

• Nextech VI Oncology SCSp, Nextech VI GP S.a. r.l., Ian Charoub, Costas Constantinides, and Rocco Sgobbo have collectively reported beneficial ownership of 3,553,585 shares of Tyra Biosciences, Inc. common stock.
• This holding represents 6.0% of the total outstanding shares of common stock.
• The reporting date for this ownership stake is June 30, 2026.
• The filing clarifies that Nextech VI LP holds the shares, Nextech VI GP is the general partner, and Charoub, Constantinides, and Sgobbo are managers of Nextech VI GP, possessing the power to direct voting and disposition of the shares.
• The reporting persons expressly disclaim status as a 'group' for the purposes of this Schedule 13G.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this filing as neutral, as it primarily reports a change in beneficial ownership without providing new operational or financial performance data.

Positives

• Significant institutional ownership reported, indicating investor interest in Tyra Biosciences.
• Clear disclosure of beneficial ownership structure and control over shares.

Negatives

• No new financial or operational performance data is provided in this filing.
• The filing does not offer insights into the investment strategy or rationale behind the ownership stake.

Risks

• Potential for future changes in beneficial ownership that could impact stock price.
• The concentration of voting power among a few individuals could influence corporate decisions.

Future Outlook

This filing does not contain forward-looking statements or guidance regarding the company's future performance.

Management Comments

• The Reporting Persons expressly disclaim status as a 'group' for purposes of this Schedule 13G.
• Each of Nextech VI GP, Charoub, Constantinides and Sgobbo possesses power to direct the voting and disposition of the securities held by Nextech VI LP.

Industry Context

StockSavvy.ai notes that Schedule 13G filings are routine disclosures for significant institutional investors crossing certain ownership thresholds. This filing indicates a notable stake by Nextech VI Oncology in Tyra Biosciences, a biotechnology company, which is common in the sector where institutional capital plays a crucial role in funding research and development.

Stakeholder Impact

• Shareholders: May view the increased institutional ownership positively, potentially indicating confidence in the company's prospects, but also noting the concentration of voting power.
• Management: Will be aware of the significant stake held by Nextech VI Oncology and its potential influence on corporate governance and strategic decisions.

Next Steps

• Monitor future filings for any changes in beneficial ownership by Nextech VI Oncology or other significant investors.
• Observe Tyra Biosciences' operational and financial performance for insights into the investment thesis.

Key Dates

Keywords

Tyra Biosciences, Nextech VI Oncology, Schedule 13G, Beneficial Ownership, Institutional Investor, Common Stock, SEC Filing